

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>TAS Partners, LLC</u> (Last) (First) (Middle) 36 WOODMAN ROAD (Street) CHESTNUT HILL MA 02467 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 06/21/2016	3. Issuer Name and Ticker or Trading Symbol <u>SELECTA BIOSCIENCES INC [SELB]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input type="checkbox"/> Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	21,013	I	See Footnote ⁽¹⁾⁽⁴⁾
Common Stock	19,702	I	See Footnote ⁽²⁾⁽⁴⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series B Convertible Preferred Stock	(3)	(3)	Common Stock	157,864	(3)	I	See Footnote ⁽¹⁾⁽⁴⁾
Series B Convertible Preferred Stock	(3)	(3)	Common Stock	157,864	(3)	I	See Footnote ⁽²⁾⁽⁴⁾
Series C Convertible Preferred Stock	(3)	(3)	Common Stock	153,742	(3)	I	See Footnote ⁽¹⁾⁽⁴⁾
Series C Convertible Preferred Stock	(3)	(3)	Common Stock	93,954	(3)	I	See Footnote ⁽²⁾⁽⁴⁾
Series D Convertible Preferred Stock	(3)	(3)	Common Stock	63,547	(3)	I	See Footnote ⁽¹⁾⁽⁴⁾
Series D Convertible Preferred Stock	(3)	(3)	Common Stock	51,355	(3)	I	See Footnote ⁽²⁾⁽⁴⁾
Series E Convertible Preferred Stock	(3)	(3)	Common Stock	84,421	(3)	I	See Footnote ⁽¹⁾⁽⁴⁾
Series E Convertible Preferred Stock	(3)	(3)	Common Stock	79,156	(3)	I	See Footnote ⁽²⁾⁽⁴⁾
Common Warrants	07/24/2015	07/24/2018	Common Stock	5,326	17.55	I	See Footnote ⁽¹⁾⁽⁴⁾
Common Warrants	07/24/2015	07/24/2018	Common Stock	4,304	17.55	I	See Footnote ⁽²⁾⁽⁴⁾

1. Name and Address of Reporting Person*
TAS Partners, LLC
 (Last) (First) (Middle)
 36 WOODMAN ROAD
 (Street)
 CHESTNUT HILL MA 02467
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
Leukon Investments, LP
 (Last) (First) (Middle)
 36 WOODMAN ROAD

(Street)		
CHESTNUT HILL	MA	02467

(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
<u>SPRINGER TIMOTHY A</u>		

(Last)	(First)	(Middle)
36 WOODMAN ROAD		

(Street)		
CHESTNUT HILL	MA	02467

(City)	(State)	(Zip)

Explanation of Responses:

- Held by Leukon Investments LP ("Leukon").
- Held by TAS Partners, LLC ("TAS").
- The preferred stock is convertible at any time, at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.
- LKST, Inc. is the general partner of Leukon. Timothy Springer is the president of LKST, Inc. and the managing member of TAS. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

TAS Partners, LLC By: /s/
Timothy A. Springer, Ph.D., 06/21/2016
Manager

Leukon Investments LP By:
LKST, Inc., its general partner 06/21/2016
By: /s/ Timothy A. Springer,
Ph.D., President

/s/ Timothy A. Springer, Ph.D. 06/21/2016

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.